Smith & Nephew plc vs State Street Technology Select Sector SPDR ETF — how do they compare? Smith & Nephew plc trades at $30.23 (market cap $12.54B), while State Street Technology Select Sector SPDR ETF trades at $188.4. The key difference: Smith & Nephew plc pays a 2.65% dividend while State Street Technology Select Sector SPDR ETF pays none, and State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| SNN | XLK | |
|---|---|---|
Market Cap | $12.54B | — |
Sector | Health | Sector/Thematic |
52-Week High | $38.70 | $198.21 |
52-Week Low | $28.73 | $127.49 |
Enterprise Value | $15.57B | — |
Dividend Yield | 2.65% | — |
Signals from Pluang's Aura AI — not financial advice
SNN trades at $29.87, down 0.71% on the day, with a bearish technical signal. The company reported Q2 2026 revenue growth of 1.6%, below expectations, leading to a reduced full-year outlook. Fundamentals show improvement with 2025 revenue of $6.16B and net income of $625M, yielding a 10.08% margin, though recent earnings have been mixed. The balance sheet remains solid with $619M in cash and a debt-to-asset ratio of 29.75% for 2025.
The outlook is cautious due to near-term operational weakness, particularly in U.S. Orthopaedics, offset by innovation in robotics and wound care. Risks include execution challenges and competitive pressures, while analyst sentiment is predominantly Hold. The stock's valuation appears reasonable with a P/E of 20.41, but growth catalysts are needed for significant upside.
XLK trades at $188.86, up 1.36% with a bullish technical signal from moving averages. The ETF shows strong momentum near resistance at $189, supported by sector inflows and earnings growth. Recent news highlights tech sector leadership and investor accumulation during selloffs, though concentration risk remains a concern.
Outlook is positive with tech earnings driving gains, but overbought RSI and high dependence on mega-caps pose near-term risks. Long-term growth hinges on AI adoption and sector diversification, with analysts favoring broad tech exposure alternatives for valuation advantages.
Trailing returns across standard periods
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →